Pulmonary Arterial Hypertension Complicating Connective Tissue Diseases

ABSTRACT

Pulmonary arterial hypertension (PAH) may complicate diverse connective tissue diseases (CTDs) such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and mixed CTD (MCTD) and is an important cause of morbidity and mortality in this context. From a histological standpoint, the pulmonary vascular lesions in PAH complicating CTD are similar to those observed in idiopathic PAH (IPAH). However, prognosis and responsiveness to therapy are distinctly worse in PAH associated with CTD. PAH is most common in SSc (affecting up to 20% of patients with SSc), and most of the data regarding incidence, clinical features, and therapy of CTD-associated PAH are derived from patients with SSc (scleroderma). Although PAH may involve other CTDs, data are more limited (primarily small, uncontrolled series and case reports). Treatment strategies for PAH associated with CTD are similar to but are distinctly less effective than those for IPAH. Lung transplantation may be offered for a subset of patients with CTD-associated PAH, but results are less favorable than for IPAH due to comorbidities and specific complications associated with CTD (e.g., esophageal involvement, aspiration with SSc).

Pulmonary arterial hypertension - connective tissue diseases - systemic sclerosis - scleroderma - pulmonary vasodilator therapy

REFERENCES

• 1 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
• 2 Kawut S M, Taichman D B, Archer-Chicko C L, Palevsky H I, Kimmel S E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.  Chest. 2003;  123 344-350
• 3 Fisher M R, Mathai S C, Champion H C et al.. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.  Arthritis Rheum. 2006;  54 3043-3050
• 4 Jimenez S A, Derk C T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.  Ann Intern Med. 2004;  140 37-50
• 5 Tan F K. Systemic sclerosis: the susceptible host (genetics and environment).  Rheum Dis Clin North Am. 2003;  29 211-237
• 6 LeRoy E C, Black C, Fleischmajer R et al.. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.  J Rheumatol. 1988;  15 202-205
• 7 Mayes M D, Lacey Jr J V, Beebe-Dimmer J et al.. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.  Arthritis Rheum. 2003;  48 2246-2255
• 8 Mayes M D. Scleroderma epidemiology.  Rheum Dis Clin North Am. 2003;  29 239-254
• 9 Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo.  Arch Dermatol Res. 1991;  283 366-371
• 10 Allcock R J, Forrest I, Corris P A, Crook P R, Griffiths I D. A study of the prevalence of systemic sclerosis in northeast England.  Rheumatology (Oxford). 2004;  43 596-602
• 11 Battle R W, Davitt M A, Cooper S M et al.. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.  Chest. 1996;  110 1515-1519
• 12 Stupi A M, Steen V D, Owens G R, Barnes E L, Rodnan G P, Medsger Jr T A. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.  Arthritis Rheum. 1986;  29 515-524
• 13 Sacks D G, Okano Y, Steen V D, Curtiss E, Shapiro L S, Medsger Jr T A. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody.  J Rheumatol. 1996;  23 639-642
• 14 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.  Rheumatology (Oxford). 2001;  40 453-459
• 15 Hachulla E, Gressin V, Guillevin L et al.. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.  Arthritis Rheum. 2005;  52 3792-3800
• 16 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
• 17 Peacock A J, Murphy N F, McMurray J J, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension.  Eur Respir J. 2007;  30 104-109
• 18 Condliffe R, Kiely D G, Peacock A J et al.. Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era.  Am J Respir Crit Care Med. 2009;  179 151-157
• 19 LeRoy E C. Systemic sclerosis: a vascular perspective.  Rheum Dis Clin North Am. 1996;  22 675-694
• 20 Sgonc R, Gruschwitz M S, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.  Arthritis Rheum. 2000;  43 2550-2562
• 21 Cerinic M M, Valentini G, Sorano G G et al.. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.  Semin Arthritis Rheum. 2003;  32 285-295
• 22 Altman R D, Medsger Jr T A, Bloch D A, Michel B A. Predictors of survival in systemic sclerosis (scleroderma).  Arthritis Rheum. 1991;  34 403-413
• 23 Denton C P, Bickerstaff M C, Shiwen X et al.. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.  Br J Rheumatol. 1995;  34 1048-1054
• 24 Distler O, Del Rosso A, Giacomelli R et al.. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.  Arthritis Res. 2002;  4 R11
• 25 Choi J J, Min D J, Cho M L et al.. Elevated vascular endothelial growth factor in systemic sclerosis.  J Rheumatol. 2003;  30 1529-1533
• 26 Hebbar M, Peyrat J P, Hornez L, Hatron P Y, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.  Arthritis Rheum. 2000;  43 889-893
• 27 Okano Y, Steen V D, Medsger Jr T A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis.  Arthritis Rheum. 1992;  35 95-100
• 28 Negi V S, Tripathy N K, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.  J Rheumatol. 1998;  25 462-466
• 29 Tamby M C, Chanseaud Y, Humbert M et al.. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension.  Thorax. 2005;  60 765-772
• 30 Fritzler M J, Hart D A, Wilson D et al.. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis.  J Rheumatol. 1995;  22 1688-1693
• 31 Grigolo B, Mazzetti I, Meliconi R et al.. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.  Clin Exp Immunol. 2000;  121 539-543
• 32 Nicolls M R, Taraseviciene-Stewart L, Rai P R, Badesch D B, Voelkel N F. Autoimmunity and pulmonary hypertension: a perspective.  Eur Respir J. 2005;  26 1110-1118
• 33 Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.  Clin Exp Immunol. 1999;  116 174-180
• 34 Chizzolini C, Raschi E, Rezzonico R et al.. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.  Arthritis Rheum. 2002;  46 1602-1613
• 35 Tamby M C, Humbert M, Guilpain P et al.. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension.  Eur Respir J. 2006;  28 799-807
• 36 Terrier B, Tamby M C, Camoin L et al.. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  177 1128-1134
• 37 Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.  Chest. 2006;  130 182-189
• 38 Jais X, Launay D, Yaici A et al.. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.  Arthritis Rheum. 2008;  58 521-531
• 39 Austin E D, Loyd J E. Genetics and mediators in pulmonary arterial hypertension.  Clin Chest Med. 2007;  28 43-57 vii-viii
• 40 Morse J H, Deng Z, Knowles J A. Genetic aspects of pulmonary arterial hypertension.  Ann Med. 2001;  33 596-603
• 41 Trembath R C, Thomson J R, Machado R D et al.. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.  N Engl J Med. 2001;  345 325-334
• 42 Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.  J Rheumatol. 2002;  29 2379-2381
• 43 Tew M B, Arnett F C, Reveille J D, Tan F K. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.  Arthritis Rheum. 2002;  46 2829-2830
• 44 Wipff J, Kahan A, Hachulla E et al.. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension.  Rheumatology (Oxford). 2007;  46 622-625
• 45 Schachna L, Wigley F M, Chang B, White B, Wise R A, Gelber A C. Age and risk of pulmonary arterial hypertension in scleroderma.  Chest. 2003;  124 2098-2104
• 46 Chang B, Schachna L, White B, Wigley F M, Wise R A. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.  J Rheumatol. 2006;  33 269-274
• 47 Steen V, Medsger Jr T A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.  Arthritis Rheum. 2003;  48 516-522
• 48 Allanore Y, Borderie D, Avouac J et al.. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.  Arthritis Rheum. 2008;  58(1) 284-291
• 49 Hsiao S H, Lee C Y, Chang S M, Lin S K, Liu C P. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging.  J Am Soc Echocardiogr. 2006;  19 507-514
• 50 Lee C Y, Chang S M, Hsiao S H, Tseng J C, Lin S K, Liu C P. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion.  Echocardiography. 2007;  24 118-125
• 51 Meune C, Avouac J, Wahbi K et al.. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients.  Arthritis Rheum. 2008;  58 1803-1809
• 52 Overbeek M J, Lankhaar J W, Westerhof N et al.. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.  Eur Respir J. 2008;  31 1160-1166
• 53 Williams M H, Handler C E, Akram R et al.. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.  Eur Heart J. 2006;  27 1485-1494
• 54 Forfia P R, Mathai S C, Fisher M R et al.. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  177 1364-1369
• 55 Williams M H, Das C, Handler C E et al.. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.  Heart. 2006;  92 926-932
• 56 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
• 57 Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972-2002.  Ann Rheum Dis. 2007;  66 940-944
• 58 Bulkley B H, Ridolfi R L, Salyer W R, Hutchins G M. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction.  Circulation. 1976;  53 483-490
• 59 Fernandes F, Ramires F J, Arteaga E, Ianni B M, Bonfá E S, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study.  J Card Fail. 2003;  9 311-317
• 60 Pope J. An update in pulmonary hypertension in systemic lupus erythematosus: do we need to know about it?.  Lupus. 2008;  17 274-277
• 61 Haas C. Pulmonary hypertension associated with systemic lupus erythematosus [in French].  Bull Acad Natl Med. 2004;  188 985-997, discussion 997
• 62 Sullivan W D, Hurst D J, Harmon C E et al.. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.  Medicine (Baltimore). 1984;  63 92-107
• 63 Launay D, Hachulla E, Hatron P Y, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature.  Medicine (Baltimore). 2007;  86 299-315
• 64 Budhiraja R, Tuder R M, Hassoun P M. Endothelial dysfunction in pulmonary hypertension.  Circulation. 2004;  109 159-165
• 65 Sitbon O, Humbert M, Jaïs X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
• 66 Humbert M, Sitbon O, Chaouat A et al.. Pulmonary arterial hypertension in France: results from a national registry.  Am J Respir Crit Care Med. 2006;  173 1023-1030
• 67 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
• 68 Simonneau G, Barst R J, Galie N Treprostinil Study Group et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 69 Tapson V F, Gomberg-Maitland M, McLaughlin V V et al.. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.  Chest. 2006;  129 683-688
• 70 Farber H W, Graven K K, Kokolski G, Korn J H. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.  J Rheumatol. 1999;  26 1195-1196
• 71 Palmer S M, Robinson L J, Wang A, Gossage J R, Bashore T, Tapson V F. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.  Chest. 1998;  113 237-240
• 72 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
• 73 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 74 Denton C P, Humbert M, Rubin L, Black C M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.  Ann Rheum Dis. 2006;  65 1336-1340
• 75 Girgis R E, Mathai S C, Krishnan J A, Wigley F M, Hassoun P M. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.  J Heart Lung Transplant. 2005;  24 1626-1631
• 76 Barst R J, Langleben D, Frost A STRIDE-1 Study Group et al. Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
• 77 Girgis R E, Frost A E, Hill N S et al.. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.  Ann Rheum Dis. 2007;  66 1467-1472
• 78 Galiè N, Olschewski H, Oudiz R J Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.  Circulation. 2008;  117 3010-3019
• 79 Iannone F, Riccardi M T, Guiducci S et al.. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.  Ann Rheum Dis. 2008;  67 1121-1126
• 80 Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.  Expert Opin Pharmacother. 2006;  7 1487-1501
• 81 Galiè N, Ghofrani H A, Torbicki A Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group et al. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
• 82 Badesch D B, Hill N S, Burgess G SUPER Study Group et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.  J Rheumatol. 2007;  34 2417-2422
• 82a Galie N, Brundage B H, Ghofrani H A et al. Tadalafil therapy for pulmonary arterial hypertension.  Circulation. 2009;  119 2894-2903
• 83 Simonneau G, Rubin L J, Galiè N PACES Study Group et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.  Ann Intern Med. 2008;  149 521-530
• 84 Mathai S C, Girgis R E, Fisher M R et al.. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.  Eur Respir J. 2007;  29 469-475
• 85 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
• 86 Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension.  J Clin Invest. 2005;  115 1461-1463
• 87 Schermuly R T, Dony E, Ghofrani H A et al.. Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821
• 88 Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension.  N Engl J Med. 2005;  353 1412-1413
• 89 Patterson K C, Weissmann A, Ahmadi T, Farber H W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.  Ann Intern Med. 2006;  145 152-153
• 90 Schachna L, Medsger Jr T A, Dauber J H et al.. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.  Arthritis Rheum. 2006;  54 3954-3961